FIELD: medicine.
SUBSTANCE: invention includes description of novel pharmaceutical combination, pharmaceutical composition, which includes said combination, application of said combination for obtaining medication and commercial packing. Combination includes (a) at least one anti-inflammatory agent, selected from group, which includes inhibitors of topoisomerase I and inhibitors of topoisomerase II, and (b) epothilone B derivative of formula (I), and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or successive application.
EFFECT: obtaining of effective combination for treatment of proliferative disease, namely disease connected with considerable tumor and resistant to other medications.
12 cl
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS CONTAINING TRANSDUCTION SIGNAL INHIBITOR AND EPOTILONE DERIVATIVE | 2002 |
|
RU2313345C2 |
| COMBINATIONS CONTAINING EPOTHILONES AND ANTIMETABOLITES | 2003 |
|
RU2346686C2 |
| COMBINATIONS CONTAINING EPOTHILONES AND PROTEIN KINASE INHIBITORS AND PHARMACEUTICAL APPLICATION THEREOF | 2005 |
|
RU2423980C2 |
| COMBINATIONS CONTAINING ANTIDIARRHEAL AGENT AND EPOTHYLON OR EPOTHYLON DERIVATIVES | 2002 |
|
RU2330661C2 |
| COMBINATIONS INCLUDING EPOTHILONES, AND THEIR PHARMACEUTICAL APPLICATION | 2002 |
|
RU2375058C2 |
| COMBINATIONS INCLUDING EPOTHILONE DERIVATIVES AND ALKYLATING AGENTS | 2003 |
|
RU2341260C2 |
| COMBINATION CONTAINING IRON COMPLEX AND ANTINEOPLASTIC AGENT, AND USE THEREOF | 2007 |
|
RU2469721C2 |
| TREATMENT OF PROLIFERATIVE DISEASES WITH EPOTHILONE DERIVATIVES AND RADIATION | 2004 |
|
RU2381799C2 |
| SYNERGIC METHODS AND COMPOSITIONS FOR CANCER TREATMENT | 2001 |
|
RU2264217C2 |
| COMPOSITIONS CONTAINING SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | 2002 |
|
RU2333754C2 |
